ArticleFrontiers in oncology2022

Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study.

Haoqi Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.